How Phio Pharmaceuticals Is Reawakening the Immune System to Fight Cancer
Description
As part of our official DealFlow Discovery Conference Interview Series, produced by Mission Matters, along with our partner DealFlow Events, we’re showcasing the innovative companies presenting at the DealFlow Discovery Conference and the executives behind them.
Today’s spotlight features Robert Bitterman, CEO & President of Phio Pharmaceuticals, who discusses how the company’s INTASYL™ RNA platform is engineered to reactivate immune cells directly within the tumor microenvironment — opening the door to safer, more targeted cancer therapies.
In this episode, Adam Torres interviews Robert Bitterman, CEO and President of Phio Pharmaceuticals, about the company’s mission to create new pathways toward a cancer-free future. Robert explains how Phio’s INTASYL™ platform uses targeted RNA technology to reactivate immune cells inside the tumor microenvironment, potentially offering a safer and more effective approach to treating cutaneous squamous cell carcinoma. He also shares early clinical data, the next steps toward pivotal trials, and why education and innovation remain at the heart of Phio’s work.
Follow Adam on Instagram at https://www.instagram.com/askadamtorres/ for up to date information on book releases and tour schedule.
Apply to be a guest on our podcast:
https://missionmatters.lpages.co/podcastguest/
Visit our website:
More FREE content from Mission Matters here: https://linktr.ee/missionmattersmedia
Learn more about your ad choices. Visit podcastchoices.com/adchoices
United States
